Loading
A phase 2 trial of Capecitabine, Fluorouracil, Atezolizumab in colorectal cancer, run by Hoffmann-La Roche, active and no longer recruiting.
A Study of Atezolizumab With or Without Tiragolumab Following Neoadjuvant Chemoradiotherapy in Participants With Locally Advanced Rectal Cancer is a phase 2 interventional study registered as NCT05009069 by Hoffmann-La Roche, with 58 participants enrolled, started 2022-03-18 and due to reach its primary completion in 2023-11-21. Interventions recorded: Radiotherapy, Capecitabine, Fluorouracil, Atezolizumab, Tiragolumab. Conditions listed: Rectal Neoplasms, Rectal Cancer. No results are recorded here; the registry entry is the source.
Shares TIGIT blockade, Tiragolumab, Atezolizumab, Immune checkpoint inhibitors.
Shares TIGIT blockade, Tiragolumab, Atezolizumab, Roche / Genentech.
Shares Tiragolumab, Atezolizumab, Immune checkpoint inhibitors.
Shares TIGIT blockade, Tiragolumab, Atezolizumab, Immune checkpoint inhibitors.
Shares Tiragolumab, Atezolizumab, Roche / Genentech.
Shares Atezolizumab, Roche / Genentech, Immune checkpoint inhibitors.
Shares Atezolizumab, Fluorouracil (5-FU), Rectal cancer, Immune checkpoint inhibitors.
Shares Atezolizumab, Colorectal cancer, Immune checkpoint inhibitors.